Ultradian variation of nerve growth factor plasma levels in healthy and schizophrenic subjects

International Journal of Immunopathology and Pharmacology

Volumn 17, Issue 3, 2004, Pages 367-372

  Bersani, G ^a   Iannitelli, A ^a   Massoni, E ^a   Garavini, A ^a   Grilli, A ^b   Di Giannantonio, M ^b   Conti, C M V ^b   Pancheri, P ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Biological rhythms; Nerve Growth Factor; Neurotrophins; Schizophrenia

Indexed keywords

NERVE GROWTH FACTOR; NEUROTROPHIN;

ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOLOGY; LIGHT DARK CYCLE; LONG TERM MEMORY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REGULATORY MECHANISM; SCHIZOPHRENIA; SUPRACHIASMATIC NUCLEUS; ULTRADIAN RHYTHM;

EID: 8344245448     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200401700316     Document Type: Article

References (33)

1. Bina K.G. and B. Rusak. 1996. Nerve growth factor phase shifts circadian activity rhythms in Syrian hamsters. Neurosci. Lett. 206:97.
2. Golombek D.A., M.W. Hurd, K.F. Lee and M.R. Ralph. 1996. Mice lacking the p75 (NGFR) receptor exhibit abnormal responses to light. Biol. Rhythm. Res. 27:409.
3. Liang F.Q., G. Allen and D. Earnest. 2000. Role of Brain-Derived Neurotrophic Factor in circadian regulation of the suprachiasmatic pacemaker by light. J. Neurosci. 20:2978.
4. Barde Y.A. 1990. The nerve growth factor family. Progr. Growth Factor Res. 2:237.
5. Aloe L. and L. Calzà. 2004. NGF and related molecules in health and disease. In Program Brain Research, ed. Elsevier Amsterdam The Netherlands, p. 146.
6. Iannitelli A., G. Bersani and L. Aloe. 1998. Dati acquisiti ed ipotesi emergenti sul ruolo delle neurotrofine, in particolare dell'NGF, in patologie di natura psichiatrica. Giorn. Ital. Psicopat. 4:383.
7. Aloe L., A. Iannitelli, G. Bersani, E. Alleva, F. Angelucci, P. Maselli and L. Manni. 1997. Haloperidol administration in humans lowers plasma Nerve Growth Factor level: evidence that sedation induces opposite effects to arousal. Neuropsychobiol. 36:65.
8. Bersani G., A. Iannitelli, P. Maselli, P. Pancheri, L. Aloe, F. Angelucci and E. Alleva. 1999. Low nerve growth factor plasma levels in schizophrenic patients: a preliminary study. Schizophr. Res. 37:201.
9. Iannitelli A., M. Fiore, F. Angelucci and G. Bersani. 1999. NGF e schizofrenia. Le Scienze 369:84.
10. Aloe L., A. Iannitelli, F. Angelucci, G. Bersani and M. Fiore. 2000. Studies in animal models and humans suggesting a role of nerve growth factor in schizophrenia-like disorders. Behav. Pharmacol. 11:235.
11. Bersani G., A. Iannitelli, M. Fiore, F. Angelucci and L. Aloe. 2000. Data and hypotheses on the role of nerve growth factor and other neurotrophins in psychiatric disorders. Med. Hypot. 55:199.
12. Fiore M., F. Angelucci, L. Aloe, A. Iannitelli and J. Korf. 2003. Nerve Growth Factor and Brain-Derived Neurotrophic Factor in schizophrenia and depression: findings in humans and in animal models. Curr. Neuropharmacol. 1:1.
13. Levi-Montalcini R., L. Aloe and E. Alleva. 1990. A role of nerve growth factor in nervous, endocrine and immune systems. Progr. Neuro Endocrinol. Immunol. 3:1.
14. American Psychiatric Association. 1994. In Diagnostic and Statistical Manual of Mental Disorders. IV ed. (DSM-IV) American Psychiatric Association Washington DC, p.1.
15. Andreasen N.C. and S.A. Olsen. 1982. Negative v positive schizophrenia. Definition and validation. Arch. Gen. Psychiatry 39:789.
16. Kay S.R., L.A. Opler and J.P. Lindenmayer. 1989. The positive and negative syndrome scale (PANSS): rationale and standardization. Br. J. Psychiatry 155:59.
17. Oei T.P., L. Evans and G.M. Crook. 1990. Utility and validity of the STAI with anxiety disorder patients. Br. J. Clin. Psychol. 29:429.
18. Bracci-Laudiero L., L. Aloe, R. Levi-Montalcini, C. Buttinelli, D. Schilter, S. Gillessen and U. Otten. 1992. Multiple sclerosis patients express increased levels of β-NGF factor in cerebrospinal fluid. Neurosci. Lett. 147:9.
19. Rao M.L., G. Gross, B. Strebel, A. Halaris, G. Huber, P. Braunig and M. Marler. 1994. Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biol. Psychiatry 35:151.
20. Van Cauter E., P. Linkowski, M. Kerkhofs, P. Hubain, M. L'Hermite-Balériaux, R. Leclercq, M. Brasseur, G. Copinschi and J. Mendlewicz. 1991. Circadian and sleep-related endocrine rhythms in schizophrenia. Arch. Gen. Psychiatry 48:348.
21. Fanget F., B. Claustrat, J. Dalery, J. Brun, J.-L. Terra, M. Marie-Cardine and J. Guyotat. 1989. Nocturnal plasma melatonin levels in schizophrenic patients. Biol. Psychiatry 25:499.
22. GarciaMaurino J-E., J. Boja, F. Lopez-Munoz and J.L. Calvo. 1992. Immunohistochemical localization of nerve growth factor in the rat pineal gland. Brain Res. 585:255.
23. Serrano T., L.C. Lorigados and S. Armenteros. 1996. Nerve growth factor levels in normal human sera. Neuro Report 8:179.
24. Kapas L., F. Obal Jr., A. Book, J. Schweitzer, R. Wiley and J. Krueger. 1996. The effects of immunolesions of nerve growth factor-receptive neurons by 192 Ig G-saporin on sleep. Brain Research 712:53.
25. Cirelli C. and G. Tononi. 2000. Differential expression of plasticity-related genes in waking and sleep and their regulation by the noradrenergic system. J. Neurosci. 15:9187.
26. Prosser R.A., E.S. Macdonald and H.C. Heller. 1994. c-fos mRNA in the suprachiasmatic nuclei in vitro shows a circadian rhythm and responds to a serotonergic agonist. Brain Res. 25:151.
27. Kemali D., M. Maj, M.G. Ariano and N. Lovero. 1985. 24-hour plasma levels of prolactin, cortisol, growth hormone and catecholamines in schizophrenic patients. Neuropsychobiol. 14:109.
28. Rao M.L., B. Strebel, A. Halaris, G. Gross, P. Braunig, G. Huber and M. Marler. 1995. Circadian rhythm of vital signs, norepinephrine, epinephrine, thyroid hormones, and cortisol in schizophrenia. Psychiatry Res. 57:21.
29. Lorusso L., I.K. Hart, B. Giometto, R. Pezzani, J.C. Broome, D. Gritti, C. Gasparetto and G. Ricevuti. 2004. Immunological Features of Neurological Paraneoplastic Syndromes. Int. J. Immunopathol. Pharmacol. 17:135
30. Appert-Collin A., F.H.T. Duong, P. Passilly-Degrace, J.-P. Gies, J.-M. Warter and P. Poindron. 2004. Quantification of neurotrophin mRNA expression in PMN mouse: modulation by Xaliproden. Int. J. Immunopathol. Pharmacol. 17:157.
31. Kempuraj D., B. Madhappan, R. Sheeladevi, M. Nazer, S. Christodoulou, J. Reginald, N. Suthinthirarajan and A. Namasivayam. 2004. T lymphocyte subsets and immunoglobulins in intracranial tumor patients before and after treatment, and based on histological type of tumors. Int. J. Immunopathol. Pharmacol. 17:57.
32. Addolorato G., C. Ancona, E. Capristo and G. Gasbarrini. 2003. Metadoxine in the treatment of acute and chronic alcoholism: a review. Int. J. Immunopathol. Pharmacol. 16:207
33. Cooper E.L. 2003. Neuroimmunology of autism: A multifaceted hypothesis. Int. J. Immunopathol. Pharmacol. 16:289